Tabula Rasa Healthcare

Tabula Rasa Healthcare, Inc. is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services. Its brands include CareKinesis, Capstone Risk Adjustment Services, PACElogic, TruChart, PeakTPA, PersonifilRx, and Pharmastar. The MedWise HealthCare segment provides Medication Therapy Management, or MTM, software and services for Medicare, Medicaid, and commercial health plans, and also provides a cloud-based patient engagement software and services. It offers cloud-based software and clinical pharmacist services through its brands, including MedWise, SinfoníaRx, RxCompanion, PrescribeWellness, and DoseMeRx. The company was founded by Calvin H. Knowlton, Orsula V. Knowlton, and Michael Greenhalgh in April 2009 and is headquartered in Moorestown, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Tabula Rasa HealthCare reports robust Q4 growth and strategic investments

Tabula Rasa HealthCare's Q4 2022 performance reflects strong revenue growth and strategic initiatives to enhance profitability.
While facing challenges in technology-enabled solutions revenue and execution risks, the company is well-positioned for growth.
Opportunities in automation investments and MedWise platform expansion offer avenues for sustained revenue growth and market impact.

Tabula Rasa HealthCare (TRHC) excels in Q1 2023 earnings, eyes expansion

Tabula Rasa HealthCare (TRHC) delivered strong financial performance in Q1 2023, driven by revenue growth, profitability focus, and strategic initiatives.
The company faces challenges from drug price inflation and contract turnover impact but is well-positioned for future expansion and market penetration.
TRHC's emphasis on customer-centric strategies, PACE program growth, and efficient resource management sets the stage for continued success and revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tabula Rasa provides state-of-the-art medication management through a combination of technology, science and services that reduces costs, improves the quality of care and decreases the risks associated with ineffective medication plans.

MOORESTOWN, N.J., Aug.  19, 2020  (GLOBE NEWSWIRE) --   Tabula Rasa HealthCare® Corporation (NASDAQ: TRHC)  , a healthcare technology company advancing the field of medication safety, announced today an agreement to deliver clinical telepharmacy services for  Pack4U . A personalized medication delivery company, Pack4U uses a digital pharmacy network to drive patient-centric care. This new partnership will provide an integrated platform for comprehensive medication management and safety, keeping patients safe at home. 

Pack4U Selects SinfoniaRx, a Tabula Rasa HealthCare solution, for Clinical Telepharmacy Services to Improve Medication Adherence and Outcomes for Patients

Study results demonstrate an increased risk for adverse drug events in older patients by adding COVID-19 repurposed treatments to current medication regimens Study results demonstrate an increased risk for adverse drug events in older patients by adding COVID-19 repurposed treatments to current medication regimens

Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published

Tabula Rasa HealthCare, Inc. (TRHC) CEO Calvin Knowlton on Q2 2020 Results - Earnings Call Transcript

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 75.00% and -1.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Q2 Earnings Top Estimates

MOORESTOWN, N.J., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today reported financial results for the second quarter ended June 30, 2020.

Tabula Rasa HealthCare Reports Second Quarter 2020 Results

MOORESTOWN, N.J., July  22, 2020  (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2020 operating results on Wednesday, August 5, 2020 at 8 a.m. EDT. The conference call will be hosted by TRHC CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; TRHC Co-Founder, President, Chief Marketing and Business Development Officer, Orsula V. Knowlton, PharmD; and TRHC Chief Financial Officer, Brian W. Adams.  The Company’s financial results for the second quarter ended June 30, 2020, will be released after the close of the market on Tuesday, August 4, 2020.

Tabula Rasa HealthCare Second Quarter 2020 Earnings Conference Call Announcement

Cerner

CERN vs. TRHC: Which Stock Is the Better Value Option?

CERN vs. TRHC: Which Stock Should Value Investors Buy Now?

Proven MedWise platform expands to community pharmacists with personalized medication safety solutions for customized care and improved outcomes Proven MedWise platform expands to community pharmacists with personalized medication safety solutions for customized care and improved outcomes

Tabula Rasa HealthCare Launches MedWise™ SaaS Technology Integration  for Community Pharmacists

Tabula Rasa HealthCare (TRHC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Tabula Rasa HealthCare (TRHC) in Focus: Stock Moves 5.2% Higher

CERN or TRHC: Which Is the Better Value Stock Right Now?

“Clinical Documentation Excellence” Online Education Designed for Value-based Care Clinicians “Clinical Documentation Excellence” Online Education Designed for Value-based Care Clinicians

Tabula Rasa HealthCare’s Risk Adjustment Division Launches New Online Training for Physicians and Other Providers

MOORESTOWN, N.J., June  16, 2020  (GLOBE NEWSWIRE) --   Tabula Rasa HealthCare® Corporation (NASDAQ: TRHC) , a healthcare technology company advancing the field of medication safety has partnered with  Equiscript,  a 340B patient pharmacy care and technology company, to deliver advanced medication adherence reports and analytics for Equiscript and its community health center and hospital clients.

TRHC and Equiscript Launch an Advanced Medication Adherence  Reporting and Analytics Program

MOORESTOWN, N.J., June  09, 2020  (GLOBE NEWSWIRE) --  Regence  and  Tabula Rasa HealthCare® (NASDAQ: TRHC)  announced today that the companies have partnered on a virtual  clinical trial  to assess the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19. The trial examines de-identified medical information for approximately 500,000 Regence health plan members across multiple lines of business.

Regence and TRHC partner on COVID-19 virtual clinical trial to assess proposed treatment risks

Tabula Rasa Healthcare shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.

Tabula Rasa Healthcare Reaches 80-Plus Relative Strength Rating Benchmark

HMS Hlds

HMSY vs. TRHC: Which Stock Is the Better Value Option?

HMSY or TRHC: Which Is the Better Value Stock Right Now?

Goal: Improve medication safety Goal: Improve medication safety

TRHC and ASCP Sign Letter of Intent to offer MedWise™ to Consultant Pharmacists

Tabula Rasa HealthCare, Inc. (TRHC) CEO Calvin Knowlton on Q1 2020 Results - Earnings Call Transcript

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 0.00% and 1.86%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Q1 Earnings Match Estimates

Blue Apron

Beyond Meat

Canopy Growth

Chegg

EverBank Financial

Match Group

Plug Power

Revolve

Stitch Fix

Snap

Tesla

Wayfair

For investors looking for home run hits, these 15 heavily shorted stocks with huge short squeeze potential are worth a look.

15 Tightly Wound Stocks With ‘Pop’ Potential

Cardlytics

Health Catalyst Inc

Inmode Ltd

Inseego

LivePerson

Maxar Technologies

These small-cap stocks could rise by 1,000% or more in the 2020s, making them some of the best stocks to buy for the next 10 years.

10 Small-Cap Stocks to Buy for HUGE Gains in the Next 10 Years

Tabula Rasa Healthcare (TRHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tabula Rasa Healthcare (TRHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Computer Programs and Systems

CPSI vs. TRHC: Which Stock Is the Better Value Option?

CPSI vs. TRHC: Which Stock Should Value Investors Buy Now?

Tabula Rasa Healthcare (TRHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Tabula Rasa Healthcare (TRHC) is Poised to Beat Earnings Estimates Again

MOORESTOWN, N.J., April  29, 2020  (GLOBE NEWSWIRE) --  Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC) , a healthcare  technology company advancing the field of medication safety, announced today its running of a  clinical study  assessing the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19 in older adults on multiple medications.

TRHC Launches First Large Simulation Study to Assess Adverse Drug Events with proposed COVID-19 Treatments

MOORESTOWN, N.J., April  21, 2020  (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc®  (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, and Antimicrobial Therapy Inc., publisher and developer of The Sanford Guide, today announced a collaboration to make Sanford Guide easily accessible from within DoseMeRx™, TRHC’s precision dosing solution.

News for Tabula Rasa Healthcare Stock (TRHC)